Ruxolitinib

Selectively inhibits JAK1 and JAK2, used for myeloproliferative neoplasms

• ·Chronic Phase Chronic Myeloid Leukemia
• ·Chronic Myeloid Leukemia, Chronic Phase
• ·Primary Myelofibrosis (PMF)
• ·Post-polycythemia Vera Myelofibrosis (Post-PV MF)
• ·Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

No curated interaction pairs are recorded for Ruxolitinib. This is not a statement that none exist — check a full interaction reference before combining.

• Thrombocytopenia
• Anemia
• Bruising
• Dizziness

Half-life

3 hours

Protein binding

97%

Metabolised by

CYP3A4

Not recorded for Ruxolitinib. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.